Quoin Pharmaceutical’s QRX003 has been granted Orphan Drug Designation in Europe for the treatment of Peeling Skin Syndrome, providing market exclusivity and supporting the initiation of a clinical trial before year end.
Quoin Pharmaceutical’s QRX003 has been granted Orphan Drug Designation in Europe for the treatment of Peeling Skin Syndrome, providing market exclusivity and supporting the initiation of a clinical trial before year end.